<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="../images/favicon.png" type="image/x-icon">
  <title>Oral Hypoglycemics</title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="../style.css">
  <link rel="stylesheet" href="../notes.css">

</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="../index.html">
   <div class="home-navigation">
      mtr<span class="logo-dot">.</span>
    </div>
  </a>


    <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="../index.html">Home</a>
      </li>

      <li class="menu__item">
        <a class="menu__link" href="../about-temp2.html">About</a>
      </li>
    </ul>
  </nav>
  
      <!-- Toggle switch for dark mode -->
      <div class="dark-mode-toggle">
        <label class="switch-toggle">
            <input type="checkbox" id="dark-mode-toggle-checkbox">
            <span class="toggle-slider"></span>
        </label>
      </div>

      <!-- Progress Bar  -->
      <div id="progress-container">
        <div id="progress-bar"></div>
    </div>
      
<!-- SIDEBAR -->
<div id="sidebar" class="sidebar">
  <button id="closeSidebarBtn" class="btn toggle-btn close-btn">Close</button>
  <ul class="sidebar-menu toggle-menu">
    <!-- Add the list of topics dynamically using JavaScript -->
  </ul>
</div>

<!-- Toggle button to open the sidebar -->
<button id="toggleSidebarBtn" class="btn toggle-btn">&#9776;</button>

<!-- END OF SIDEBAR -->

  <main class="page-container">
    <div class="contribute-cta">
      <p>Help make this betterüíú</p>
      <span><a href="../contribute.html">Contribute here</a> </span>
    </div>


  <!-- TOPIC AND IMAGE CONTAINER  -->


      <h1>Oral Hypoglycemics</h1>


  <!-- END OF TOPIC AND IMAGE CONTAINER  -->
  


    <article class="notes">
        <a id='top'></a>
    <article>

          <!-- LEARNING OBJECTIVES CONTAINER  -->
              <div class="custom-card" id="custom-card-1">
                <div class="icon"><img src="../images/icons/light-bulb.png" alt="Icon" class="icon"></div>
                <div class="title"> 
                  <h2>What You Will Learn</h2>
                </div>
                <div class="line">
                  <p>After reading this note, you should be able to...</p>
                </div>
                <div class="content">
                  <ul>
                    <li><i>This content is not available yet.</i></li>
                </ul>
                </div>
                <div class="read-more" onclick="toggleContent('custom-card-1')">Read More üç™</div>
              </div>
            
          <!-- END OF LEARNING OBJECTIVES CONTAINER  -->
        
        
          <!-- SHOW AND HIDE OUTLINE CONTAINER  -->
            <div class="outline2">
        
              <input type="radio" name="control-2" id="show-2">
              <label for="show-2">üêµ&nbsp; &nbsp;Show Outline</label>
              <input type="radio" name="control-2" id="hide-2">
              <label for="hide-2">üôà&nbsp; &nbsp; Hide Outline</label>
              <div class="contents">
                <div class="icon-box">
                  <!-- Replace 'path/to/your/icon.png' with the actual path to your PNG icon -->
                  <img src="../images/icons/book.png" alt="Icon" class="icon">
                </div>
                <div id="tableOfContents">
                    <ol id="tocList"></ol>
                </div>
              </div>
             <div>
        
        <!-- END OF SHOW AND HIDE OUTLINE CONTAINER  -->
        
        
        <!-- READ SUMMARY CONTAINER -->
        
              <!-- Summary Overlay -->
              <div class="summary-overlay" id="summaryOverlay"></div>
        
        
              <div class="summary-card" id="summaryCard">
                
                <div class="summary-header">
                  <h3>Note Summary</h3>
                  <div class="icon-box">
                    <!-- Replace 'path/to/your/icon.png' with the actual path to your PNG icon -->
                    <img src="../images/icons/summary.png" alt="Icon" class="icon">
                  </div>
                </div>
                <div class="summary-content">
                  <!-- Summary content goes here -->
                  <p><i>This content is not available yet.</i></p>
        
                  <span class="close-btn" id="closeBtn">close</span>
                </div>
              </div>
        
              <div class="summary-trigger" id="summaryTrigger">
                <p>Click here to read a summary</p>
            </div>
        <!-- END OF READ SUMMARY CONTAINER -->
        
            <!-- BEGINNING OF NOTE -->
        
      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'>Introduction</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
              <li>Only effective for type 2 diabetes.</li>
              <li>Require the presence of endogenous insulin for their actions, so they are ineffective in type 1 diabetes.</li>
              <li>Ineffective during pregnancy and should be replaced by insulin.</li>
              <li>Ineffective and should be temporarily replaced by insulin in acute conditions where insulin requirement is increased rapidly, such as diabetic ketoacidosis and acute stress conditions like surgeries, acute infections, and myocardial infarction.</li>
            </ul>
            
            <h4>Oral Hypoglycemic Medications</h4>
            <ul>
              <li>Sulfonylureas (glipizide, glyburide, gliclazide, glimepiride)</li>
              <li>Meglitinides (repaglinide and nateglinide)</li>
              <li>Biguanides (metformin)</li>
              <li>Thiazolidinediones (rosiglitazone, pioglitazone)</li>
              <li>Œ±-Glucosidase inhibitors (acarbose, miglitol, voglibose)</li>
              <li>DPP-4 inhibitors (sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin)</li>
              <li>SGLT2 inhibitors (dapagliflozin and canagliflozin)</li>
              <li>Cycloset (bromocriptine)</li>
            </ul>
            
        </div>
      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'>Classification</a>
          </h2>
        </header>
        <div class='body'>

          <section id='heading-2-1'>
            <header>
              <h3>
                <a aria-hidden href='#heading-2-1'>Drugs that increase insulin secretion</a>
              </h3>
            </header>
            <div class='body'>


               <section id='heading-2-1-1'>
                <header>
                  <h4>
                    <a aria-hidden href='#heading-2-1-1'>Sulphonylureas</a>
                  </h4>
                </header>
                <div class='body'>
                    <ul>
                      <li>Are Sulphonamide derivatives.</li>
                      <li>Are taken orally before the main meals.</li>
                      <li>Are preferred in lean or ideal weight patients because they cause weight gain.</li>
                      <li>Promote insulin release.</li>
                      <li>Can cause hypoglycemia in diabetic as well as in non-diabetic person.</li>
                    </ul>
                    
                    <h4>Mechanism of Action</h4>
                    <p> They stimulate release of insulin from pancreas. They act on pancreatic Œ≤ cell membrane, blocking the ATP-sensitive K+ channels; this prevents K+ exit which results in depolarization. This enhances Ca+2 entry; and the rise in intracellular Ca+2 enhances the rate of insulin secretion in response to rise in blood glucose level.</p>
                    
                    <p>After chronic administration, they sensitize the target tissues (liver, muscle, and adipose tissue) to the action of insulin by increasing the number of insulin receptors.</p>

                    <h4>Classification:</h4>
                    <p><strong>1st generation agents:</strong> (e.g., chlorpropamide - withdrawn due to side effects, tolbutamide)</p>
                    <p><strong>2nd generation agents:</strong> have similar efficacy but are more potent than 1st generation agents (e.g., glibenclamide, glipizide, glimepiride):
                      <ul>
                        <li>Selection does not depend on potency but on duration of action, side effects, as well as patient‚Äôs age, renal function, and liability to develop hypoglycemia.</li>
                        <li>Long-acting members like glibenclamide (glyburide) and glimepiride can be given once daily but they cause a higher incidence of late post-meal hypoglycemia, so they are not preferred in the elderly.</li>
                        <li>Tolbutamide, gliclazide, and glipizide have a shorter duration of action, leading to less risk of prolonged hypoglycemia, making them more suitable in the elderly.</li>
                        <li>Glibenclamide is excreted by the liver and kidney, so the dose needs to be adjusted in patients with liver or renal impairment.</li>
                        <li>Gliclazide, glipizide, and tolbutamide are metabolized in the liver to inactive metabolites before excretion by the kidney, making them safe in patients with impaired renal function.</li>
                      </ul>
                    </p>
                    
                    <h4>Side effects:</h4>
                    <ul>
                      <li>Hypoglycemia.</li>
                      <li>Weight gain because insulin release stimulates appetite.</li>
                      <li>Secondary failure after months or years due to declining of beta cells function and insulin resistance.</li>
                      <li>Teratogenic in animals, so avoid during pregnancy.</li>
                    </ul>
                    
                </div>
              </section>

              <section id='heading-2-1-2'>
                <header>
                  <h4>
                    <a aria-hidden href='#heading-2-1-2'>Meglitinides</a>
                  </h4>
                </header>
                <div class='body'>

                    <h4> (e.g., repaglinide, nateglinide)</h4>
                    <ul>
                      <li>Stimulate insulin release by a similar mechanism as sulphonylureas.</li>
                      <li>Induce rapid, very short-lasting insulin release. It is administered before each major meal to boost the postprandial insulin release and control postprandial hyperglycemia.</li>
                      <li>Because of their short-lasting action, there is a lower risk of hypoglycemia.</li>
                      <li>Metabolized in the liver ‚Äì should be avoided in liver impairment.</li>
                    </ul>
                    
                </div>
              </section>

              <section id='heading-2-1-3'>
                <header>
                  <h4>
                    <a aria-hidden href='#heading-2-1-3'>Incretin Analogues</a>
                  </h4>
                </header>
                <div class='body'>

                    <h4> (e.g., exenatide)</h4>
                    <ul>
                      <li><strong>Mechanism:</strong> An analogue of the endogenous glucagon-like-peptide 1 (incretin) that is secreted from the upper small intestine in response to glucose. It enhances postprandial insulin secretion, suppresses glucagon secretion, slows gastric emptying, and decreases appetite.</li>
                      <li>Used in overweight patients, given subcutaneously, may cause nausea as a side effect.</li>
                    </ul>
                    
                </div>
              </section>

              <section id='heading-2-1-4'>
                <header>
                  <h4>
                    <a aria-hidden href='#heading-2-1-4'>Sitagliptin</a>
                  </h4>
                </header>
                <div class='body'>

                    <p> Inhibits dipeptidyl peptidase-4 enzyme that is responsible for the breakdown of GLP-1 and potentiates its action. It is administered orally.</p>

                </div>
              </section>

            </div>
          </section>

          <section id='heading-2-2'>
            <header>
              <h3>
                <a aria-hidden href='#heading-2-2'>Insulin Sensitizers</a>
              </h3>
            </header>
            <div class='body'>
               <p><strong>Increase the sensitivity of target organs to insulin</strong></p>

               <section id='heading-2-2-1'>
                <header>
                  <h4>
                    <a aria-hidden href='#heading-2-2-1'>Biguanides</a>
                  </h4>
                </header>
                <div class='body'>
                    <h4> (e.g., Metformin)</h4>

                    <h4></h4>
                    <ul>Mechanism of Action
                      <li> It prevents hyperglycemia as it:
                        <ol>
                          <li>Suppresses hepatic gluconeogenesis and glucose output.</li>
                          <li>Sensitizes the target tissues (especially muscle) to the action of insulin, enhancing glucose utilization.</li>
                          <li>Reduces intestinal absorption of glucose.</li>
                        </ol>
                      </li>
                      <li>Can be given after main meals.</li>
                      <li>Does not cause hypoglycemia because it does not promote insulin release.</li>
                      <li>Is excreted unchanged by kidneys and so may accumulate to toxic levels in renal impairment.</li>
                      <li>Does not cause weight gain, so it is preferred for overweight and obese patients with normal renal function.</li>
                      <li><strong>Other uses:</strong> Treatment of polycystic ovary syndrome (a condition of insulin resistance that contributes to hyperandrogenism, hirsutism, menstrual disorders, and infertility).</li>
                    </ul>
                    
                    <h4>Side effects:</h4>
                    <ul>
                      <li>Diarrhea, anorexia, nausea, and metallic taste.</li>
                      <li><strong>Lactic acidosis:</strong> In patients with renal impairment or liver failure.</li>
                      <li>Vitamin B12 deficiency (due to impaired absorption). Patients may need vitamin B12 injections periodically.</li>
                    </ul>
                </div>
              </section>

              <section id='heading-2-2-2'>
                <header>
                  <h4>
                    <a aria-hidden href='#heading-2-2-2'>Thiazolidinediones (glitazones) </a>
                  </h4>
                </header>
                <div class='body'>
                    <h4> (e.g., pioglitazone)</h4>

                    <h4>Mechanism of Action</h4>
                    <ul>
                      <li> Sensitizes the peripheral tissues (especially fatty tissues) to the action of insulin by activation of certain genes.</li>
                      <li>Do not promote insulin release and do not cause hypoglycemia.</li>
                    </ul>

                    <h4>Side Effects</h4>
                    <ul>
                        <li>Flatulence</li>
                        <li>Diarrhea</li>
                        <li>Abdominal pain</li>
                        <li>Distension</li>
                      </ul>
        
                </div>
              </section>

            </div>
          </section>

          <section id='heading-2-3'>
            <header>
              <h3>
                <a aria-hidden href='#heading-2-3'>Alpha Glucosidase Inhibitors</a>
              </h3>
            </header>
            <div class='body'>
                <h4> (e.g., acarbose)</h4>
                <h4>Mechanism of action</h4>
                <ul>
                  <li> Inhibits Œ±-glucosidase enzymes, responsible for the digestion of complex carbohydrates in the small intestine, preventing the postprandial rise in blood glucose.</li>
                  <li>Does not cause hypoglycemia.</li>
                </ul>

                <h4>Side Effects</h4>
            
                  <ul>
                    <li>Flatulence</li>
                    <li>Diarrhea</li>
                    <li>Abdominal pain</li>
                    <li>Distension</li>
                  </ul>
                
                

            </div>
          </section>

        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>Hypoglycemia</a>
          </h2>
        </header>
        <div class='body'>
            <h4>Precipitating Factors</h4>
            <p> Missing a meal, unusual physical exercise, overdose of insulin or oral hypoglycemic drugs, and co-administration of drugs that intensify hypoglycemia such as salicylates, sulphonamides, and cimetidine.</p>
            <p><strong>Warning signs:</strong> Sweating, tremor, tachycardia, and palpitation. (Which drugs mask these symptoms and why?)</p>

            <h4>Treatment</h4>
            <ul>
              <li>Glucose must be given orally or intravenously if the patient is unconscious.</li>
              <li>Glucagon subcutaneously or intramuscularly enhances glycogenolysis and increases hepatic glucose output. However, about 45 minutes from the onset of coma, hepatic glycogen will be exhausted and glucagon will be useless.</li>
            </ul>
        </div>
      </section>








      <hr style="margin: 3rem 0;">

      <!-- PRACTICE QUESTIONS CONTAINER -->

      <div class="custom-card" id="custom-card-2">
        <div class="icon"><img src="../images/icons/practice-questions.png" alt="Icon" class="icon"></div>
        <div class="title"> 
          <h2>Practice Questions</h2>
        </div>
        <div class="line">
          <p>Check how well you grasp the concepts by answering the following questions...</p>
        </div>
        <div class="content">
          <ol>
            <li><i>This content is not available yet.</i></li>
          </ol>
        </div>
        <div class="read-more" onclick="toggleContent('custom-card-2')">Read More üç™</div>
      </div>

      <!-- END OF PRACTICE QUESTIONS CONTAINER -->


      <!-- CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
      <div class="contact">
        <div class="comment-container">
          <div class="comment-icon">
            <!-- Add your icon image here -->
            <img src="../images/icons/comment.png" alt="Comment Icon">
          </div>
          <div class="comment-text">
            <!-- Add your text here -->
            <p>Send your comments, corrections, explanations/clarifications and requests/suggestions </p>
          </div>
          <a href="https://chat.whatsapp.com/FtDdb6uEFYzBCnTnMgm2Z1" class="comment-button">
            here
            <img src="../images/icons/whatsapp.png" alt="Image Icon">
          </a>
        </div>

        <div class="contributors-container">

          <h2 class="contributors-header">Contributors</h2>
  
        <br>
            <div class="contributor-box">
                <img class="contributor-avatar" src="../images/icons/woman.png" alt="Contributor 1 Avatar">
                <div class="contributor-info">
                    <h3 class="contributor-name">Jane Smith</h3>
                    <p class="contributor-description">She is not a real contributor.</p>
                    <div class="social-links">
                        <a href="#" target="_blank" class="social-icon">
                            <img src="../images/icons/whatsapp.png" alt="Social Icon 1">
                        </a>
                        <a href="#" target="_blank" class="social-icon">
                            <img src="../images/icons/twitter.png" alt="Social Icon 2">
                        </a>
                    </div>
                </div>
            </div>
        
            <div class="contributor-box">
                <img class="contributor-avatar" src="../images/icons/man.png" alt="Contributor 2 Avatar">
                <div class="contributor-info">
                    <h3 class="contributor-name">John Doe</h3>
                    <p class="contributor-description">He is not a real contributor.</p>
                    <div class="social-links">
                      <a href="#" target="_blank" class="social-icon">
                        <img src="../images/icons/whatsapp.png" alt="Social Icon 1">
                    </a>
                    <a href="#" target="_blank" class="social-icon">
                        <img src="../images/icons/linkedin.png" alt="Social Icon 2">
                    </a>
                    </div>
                </div>
            </div>
        
        </div>
      </div>

            <!-- END OF CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p id="popup-trigger">disclaimer</p>

          <!-- The pop-up dive content -->
          <div id="popup" class="popup">
            <p>The contents on this ‚Äòwebsite‚Äô are for educational purposes only. The creators and operators of this website make no warranties, express or implied, regarding the accuracy, currency, or completeness of the information provided on the website. They shall not be held responsible for any errors or omissions, or for any actions taken based on the information provided on this website.</p>
            <button class="popup-close" onclick="closePopup()">Close</button>
          </div>    
          <p><a href="../about-temp2.html">about</a> </p>   
          <p><a href="../contribute.html">contribute</a> </p>
          <p><a href="https://chat.whatsapp.com/FtDdb6uEFYzBCnTnMgm2Z1">say hiüëã</a> </p>
        </div>

        <div class="footer-beta">
          <p>thisisatestversion</p>
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="../main.js"></script>
<script src="../modal.js"></script>
<script src="../notes-sidebar.js"></script>
</body>
</html>
 
